You are here

  • Home
  • Archive
  • Volume 10, Issue Suppl 2
  • 781 DELTA-2: A phase 1, open-label, multicenter study of ITIL-168, an autologous tumor-infiltrating lymphocyte (TIL) cell therapy, with pembrolizumab in patients with advanced solid tumors

Article metrics

Article menu

Download PDFPDF

Regular and Young Investigator Award Abstracts
Clinical Trials In Progress
781 DELTA-2: A phase 1, open-label, multicenter study of ITIL-168, an autologous tumor-infiltrating lymphocyte (TIL) cell therapy, with pembrolizumab in patients with advanced solid tumors
Free

 

Online download statistics by month:

Online download statistics by month: November 2022 to March 2024

AbstractFullPdf
Nov 20221054046
Dec 2022170014
Jan 202316006
Feb 202312607
Mar 202310606
Apr 202314007
May 202311205
Jun 20239405
Jul 2023100011
Aug 20239206
Sep 20239805
Oct 202313404
Nov 202310004
Dec 2023130010
Jan 202410004
Feb 20247805
Mar 20249208
Total28860153